Constitutive Activation of MAPK Cascade in Acute Quadriplegic Myopathy

Annals of Neurology

Volumn 55, Issue 2, 2004, Pages 195-206

  Di Giovanni, Simone ^a   Molon, Annamaria ^a   Broccolini, Aldobrando ^b   Melcon, Gisela ^a   Mirabella, Massimiliano ^b   Hoffman, Eric P ^a,c   Servidei, Serenella ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; CORTICOSTEROID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; NEUROMUSCULAR BLOCKING AGENT; PROTEASOME; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ACUTE QUADRIPLEGIC MYOPATHY; ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG UTILIZATION; ENZYME ACTIVATION; ENZYME INDUCTION; GENE EXPRESSION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOFILAMENT; MYOPATHY; NICK END LABELING; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SIGNAL TRANSDUCTION;

ACUTE DISEASE; AGED; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICROSCOPY, ELECTRON; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MUSCULAR DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; QUADRIPLEGIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

EID: 0842304360     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10811     Document Type: Article

References (47)

1. Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992;42:2082-2087.
2. Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000;28:34-45.
3. Argov Z. Drug induced myopathy. Curr Opin Neurol 2000;13:541-545.
4. Rich MM, Bird SJ, Raps EC, et al. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997;20:665-673.
5. Sander HW, Golden M, Danon MJ. Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve 2002;26:499-505.
6. Lacomis D. Critical illness myopathy. Curr Rheumatol Rep 2002;4:403-408.
7. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin proteosome pathway. N Engl J Med 1996;335:1897-1905.
8. Helliwell TR, Wilkinson A, Griffiths RD, et al. Muscle fiber atrophy in critically ill patients is associated with loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol 1998;24:507-515
9. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997;20:316-322.
10. Matsumoto N, Nakamura T, Yasui Y, Torii J. Analysis of muscle proteins in acute quadriplegic myopathy. Muscle Nerve 2000;23:1270-1276.
11. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
12. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003;5:87-90
13. Rich MM, Pinter MJ. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001;50:26-33.
14. Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998;43:171-175.
15. Rich MM, Kraner SD, Barchi RL. Altered gene expression in steroid-treated denervated muscle. Neurobiol Dis 1999;6:515-522.
16. Jagoe RT, Lecker SH, Gomes M, Goldberg AL. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 2002;16:1697-1712.
17. Childs TE, Spangenburg EE, Vyas DR, Booth FW. Temporal alterations in protein signaling cascades during recovery from muscle atrophy. Am J Physiol Cell Physiol 2003;285:C391-C398.
18. Di Giovanni S, Mirabella M, D'Amico A, et al. Apoptotic features accompany acute quadriplegic myopathy. Neurology 2000;55:854-858.
19. Di Giovanni S, Knoblach SM, Brandoli C, et al. Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol 2003;53:454-468.
20. Seo J, Bakay M, Zhao P, et al. Building a coherent data pipeline in micorarray data analysis: visual optimization of signal/noise ratios. IEEE ICME 2003;III:461-465.
21. Church DLM, Lash AE, Leipe DD, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2001;29:11-16.
22. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
23. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000;15;14:627-644.
24. Thannickal VJ, Day RM, Klinz SG, et al. Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-beta1. FASEB J 2000;14:1741-1748.
25. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
26. Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol 2002;3:30-40.
27. Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 2000;28:N67-N77.
28. Tu Y, Wu C. Cloning, expression and characterization of a novel human Ras-related protein that is regulated by glucocorticoid hormone. Biochim Biophys Acta 1999;1489:452-456.
29. Noguchi K, Yamana H, Kitanaka C, et al. Differential role of the JNK and p38 MAPK pathway in c-Myc- and s-Myc-mediated apoptosis. Biochem Biophys Res Commun 2000;267:221-227.
30. Kang HJ, Soh Y, Kim MS, et al. Roles of JNK-1 and p38 in selective induction of apoptosis by capsaicin in ras-transformed human breast epithelial cells. Int J Cancer 2003;103:475-482.
31. Deschesnes RG, Huot J, Valerie K, Landry J. Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol Biol Cell 2001;12:1569-1582.
32. Ning W, Song R, Li C, et al. TGF-beta1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells. Am J Physiol 2002;283:L1094-L1102.
33. Hyman KM, Seghezzi G, Pintucci G, et al. Transforming growth factor-beta1 induces apoptosis in vascular endothelial cells by activation of mitogen-activated protein kinase. Surgery 2002;132:173-179.
34. Singleton JR, Baker BL, Thorburn A. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 2000;141:2945-2950.
35. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-E136.
36. Pelaia G, Cuda G, Vatrella A, et al. Effects of TGF-β and budesonide on MAPK activation and apoptosis in airway epithelial cells. Am J Respir Cell Mol Biol 2003;29:12-18.
37. Yoshida K, Kuwano K, Hagimoto N, et al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 2002;198:388-396.
38. Agusti AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:485-489.
39. Szewczyk NJ, Peterson BK, Jacobson LA. Activation of Ras and the mitogen-activated protein kinase pathway promotes protein degradation in muscle cells of Caenorhabditis elegans. Mol Cell Biol 2002;22:4181-4188.
40. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.
41. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000;11:23-35.
42. Yue J, Frey RS, Mulder KM. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene 1999;18:2033-2037.
43. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998;394:909-913.
44. Shibuya H, Yamaguchi K, Shirakabe K, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996;272:1179-1182.
45. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998;95:737-740.
46. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQAI*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002;168:4154-4163.
47. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002;59:1170-1182.